Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver
Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics, today announced a €16 million ($18 million) Seed financing round to expand DELiveri, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types. The round was co-led by 4BIO Capital and IQ Capital, with participation […] The…
We haven't written up this one. EU-Startups has the full story — the link below goes straight to it.
